{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:13:23Z","timestamp":1784182403641,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04164-w","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T14:44:35Z","timestamp":1766241875000},"page":"2377-2385","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801"],"prefix":"10.1007","volume":"28","clinical-trial-number":[{"clinical-trial-number":"nct03605771","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4886-4831","authenticated-orcid":false,"given":"Pablo","family":"Cerezuela-Fuentes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pi\u00f1ero-Madrona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Mu\u00f1oz-Couselo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Manzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-\u00c1ngel","family":"Berciano-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Majem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainara","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Ayala de Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Garc\u00eda Casta\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Guti\u00e9rrez Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Aguado de la Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Antonio","family":"Fern\u00e1ndez-Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Pu\u00e9rtolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Fra Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Rodr\u00edguez de la Borbolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Bellido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"L\u00f3pez Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Navarro P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Ram\u00f3n","family":"Garc\u00eda Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Carlos","family":"Villa Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Campos Balea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Mart\u00edn Algarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"M\u00e1rquez-Rodas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"key":"4164_CR1","first-page":"341","volume":"117","author":"T Dasgupta","year":"1963","unstructured":"Dasgupta T, Bowden L, Berg JW. Malignant melanoma of unknown primary origin. Surg Gynecol Obstet. 1963;117:341\u20135.","journal-title":"Surg Gynecol Obstet"},{"key":"4164_CR2","unstructured":"Bailey EC, Sober AJ, Tsao H, Mihm MC, Johnson TM. Chapter 124. Cutaneous Melanoma. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick\u2019s Dermatology in General Medicine [Internet]. 8th ed. New York, NY: The McGraw-Hill Companies; 2012 [cited 2025 May 19]. Available from: accessmedicine.mhmedical.com\/content.aspx?aid=56062430"},{"issue":"2","key":"4164_CR3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jaad.2018.03.021","volume":"79","author":"JF Scott","year":"2018","unstructured":"Scott JF, Conic RZ, Thompson CL, Gerstenblith MR, Bordeaux JS. Stage IV melanoma of unknown primary: a population-based study in the United States from 1973 to 2014. J Am Acad Dermatol. 2018;79(2):258-265.e4.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"4164_CR4","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.critrevonc.2010.04.007","volume":"78","author":"K Kamposioras","year":"2011","unstructured":"Kamposioras K, Pentheroudakis G, Pectasides D, Pavlidis N. Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. Crit Rev Oncol Hematol. 2011;78(2):112\u201326.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"4164_CR5","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/archderm.136.11.1397","volume":"136","author":"GM Bowen","year":"2000","unstructured":"Bowen GM, Chang AE, Lowe L, Hamilton T, Patel R, Johnson TM. Solitary melanoma confined to the dermal and\/or subcutaneous tissue: evidence for revisiting the staging classification. Arch Dermatol. 2000;136(11):1397\u20139.","journal-title":"Arch Dermatol"},{"issue":"3","key":"4164_CR6","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1245\/s10434-008-0272-9","volume":"16","author":"CC Lee","year":"2009","unstructured":"Lee CC, Faries MB, Ye X, Morton DL. Solitary dermal melanoma: beginning or end of the metastatic process? Ann Surg Oncol. 2009;16(3):578\u201384.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"4164_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1001\/archderm.140.1.99","volume":"140","author":"SM Swetter","year":"2004","unstructured":"Swetter SM, Ecker PM, Johnson DL, Harvell JD. Primary dermal melanoma: a distinct subtype of melanoma. Arch Dermatol. 2004;140(1):99\u2013103.","journal-title":"Arch Dermatol"},{"issue":"6","key":"4164_CR8","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.jaad.2024.01.082","volume":"90","author":"GN Tortorello","year":"2024","unstructured":"Tortorello GN, Li EH, Sharon CE, Shafique N, Chu EY, Ming ME, et al. Pathologic characteristics and clinical outcomes of primary dermal melanoma. J Am Acad Dermatol. 2024;90(6):1299\u2013300.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"4164_CR9","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1200\/JCO.2006.08.8310","volume":"25","author":"JR Lange","year":"2007","unstructured":"Lange JR, Palis BE, Chang DC, Soong SJ, Balch CM. Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(11):1363\u20138.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"4164_CR10","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/archotol.125.6.635","volume":"125","author":"BY Wang","year":"1999","unstructured":"Wang BY, Lawson W, Robinson RA, Perez-Ordonez B, Brandwein M. Malignant melanomas of the parotid: comparison of survival for patients with metastases from known vs unknown primary tumor sites. Arch Otolaryngol Head Neck Surg. 1999;125(6):635\u20139.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"8","key":"4164_CR11","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G","volume":"83","author":"AE Chang","year":"1998","unstructured":"Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83(8):1664\u201378.","journal-title":"Cancer"},{"issue":"1","key":"4164_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaad.2014.09.029","volume":"72","author":"JM Bae","year":"2015","unstructured":"Bae JM, Choi YY, Kim DS, Lee JH, Jang HS, Lee JH, et al. Metastatic melanomas of unknown primary show better prognosis than those of known primary: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2015;72(1):59\u201370.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"4164_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/00008390-200502000-00013","volume":"15","author":"KA Katz","year":"2005","unstructured":"Katz KA, Jonasch E, Hodi FS, Soiffer R, Kwitkiwski K, Sober AJ, et al. Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res. 2005;15(1):77\u201382.","journal-title":"Melanoma Res"},{"issue":"3","key":"4164_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/CMR.0b013e32834577ec","volume":"21","author":"AF Pfeil","year":"2011","unstructured":"Pfeil AF, Leiter U, Buettner PG, Eigentler TK, Weide B, Meier F, et al. Melanoma of unknown primary is correctly classified by the AJCC melanoma classification from 2009. Melanoma Res. 2011;21(3):228\u201334.","journal-title":"Melanoma Res"},{"issue":"6","key":"4164_CR15","first-page":"472","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472\u201392.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"4164_CR16","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/bjs.1800641114","volume":"64","author":"GW Milton","year":"1977","unstructured":"Milton GW, Shaw HM, McCarthy WH. Occult primary malignant melanoma: factors influencing survival. Br J Surg. 1977;64(11):805\u20138.","journal-title":"Br J Surg"},{"issue":"9","key":"4164_CR17","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/(SICI)1097-0142(19970501)79:9<1816::AID-CNCR26>3.0.CO;2-#","volume":"79","author":"KK Anbari","year":"1997","unstructured":"Anbari KK, Schuchter LM, Bucky LP, Mick R, Synnestvedt M, Guerry D, et al. Melanoma of unknown primary site: presentation, treatment, and prognosis\u2013a single institution study. University of Pennsylvania Pigmented Lesion Study Group. Cancer. 1997;79(9):1816\u201321.","journal-title":"Cancer"},{"issue":"11","key":"4164_CR18","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/1097-0142(196511)18:11<1399::AID-CNCR2820181104>3.0.CO;2-R","volume":"18","author":"JL Smith","year":"1965","unstructured":"Smith JL, Stehlin JS. Spontaneous regression of primary malignant melanomas with regional metastases. Cancer. 1965;18(11):1399\u2013415.","journal-title":"Cancer"},{"issue":"2","key":"4164_CR19","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/jso.25302","volume":"119","author":"Y Song","year":"2019","unstructured":"Song Y, Karakousis GC. Melanoma of unknown primary. J Surg Oncol. 2019;119(2):232\u201341.","journal-title":"J Surg Oncol"},{"issue":"4","key":"4164_CR20","first-page":"351","volume":"6","author":"SW McCarthy","year":"1974","unstructured":"McCarthy SW, Palmer AA, Bale PM, Hirst E. Naevus cells in lymph nodes. Pathology (Phila). 1974;6(4):351\u20138.","journal-title":"Pathology (Phila)"},{"issue":"1","key":"4164_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/(SICI)1097-0142(19970701)80:1<60::AID-CNCR8>3.0.CO;2-J","volume":"80","author":"B Schlagenhauff","year":"1997","unstructured":"Schlagenhauff B, Stroebel W, Ellwanger U, Meier F, Zimmermann C, Breuninger H, et al. Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations. Cancer. 1997;80(1):60\u20135.","journal-title":"Cancer"},{"issue":"12","key":"4164_CR22","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1002\/ijc.28318","volume":"133","author":"MC Hughes","year":"2013","unstructured":"Hughes MC, Wright A, Barbour A, Thomas J, Smithers BM, Green AC, et al. Patients undergoing lymphadenectomy for stage III melanomas of known or unknown primary site do not differ in outcome. Int J Cancer. 2013;133(12):3000\u20137.","journal-title":"Int J Cancer"},{"issue":"4","key":"4164_CR23","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.jaad.2022.11.040","volume":"88","author":"P Rousset","year":"2023","unstructured":"Rousset P, Dalle S, Mortier L, Dereure O, Dalac S, Dutriaux C, et al. Impact of systemic therapies in metastatic melanoma of unknown primary: a study from MELBASE, a French multicentric prospective cohort. J Am Acad Dermatol. 2023;88(4):808\u201315.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"4164_CR24","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1002\/ijc.32631","volume":"145","author":"E Ellebaek","year":"2019","unstructured":"Ellebaek E, Bastholt L, Schmidt H, Svane IM, Donia M. The real-world outcome of metastatic melanoma: Unknown primary vs known cutaneous. Int J Cancer. 2019;145(11):3173\u20134.","journal-title":"Int J Cancer"},{"issue":"6","key":"4164_CR25","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/1097-0142(19820315)49:6<1106::AID-CNCR2820490607>3.0.CO;2-0","volume":"49","author":"P Chang","year":"1982","unstructured":"Chang P, Knapper WH. Metastatic melanoma of unknown primary. Cancer. 1982;49(6):1106\u201311.","journal-title":"Cancer"},{"issue":"1","key":"4164_CR26","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/00000658-198001000-00018","volume":"191","author":"AE Giuliano","year":"1980","unstructured":"Giuliano AE, Moseley HS, Morton DL. Clinical aspects of unknown primary melanoma. Ann Surg. 1980;191(1):98\u2013104.","journal-title":"Ann Surg"},{"key":"4164_CR27","unstructured":"Scott JF, Gerstenblith MR. Melanoma of Unknown Primary. In: Scott JF, Gerstenblith MR, editors. Noncutaneous Melanoma [Internet]. Brisbane (AU): Codon Publications; 2018 [cited 2025 May 19]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK506989\/"},{"issue":"1","key":"4164_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/ijc.32229","volume":"146","author":"D Verver","year":"2020","unstructured":"Verver D, van der Veldt A, van Akkooi A, Verhoef C, Gr\u00fcnhagen DJ, Louwman WJ. Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population-based study. Int J Cancer. 2020;146(1):26\u201334.","journal-title":"Int J Cancer"},{"key":"4164_CR29","unstructured":"Informe de Posicionamiento Terap\u00e9utico de dabrafenib y trametinib (Tafinlar\u00ae y Mekinist\u00ae) en adyuvancia de melanoma [Internet]. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. 2021 [cited 2025 May 19]. https:\/\/www.aemps.gob.es\/informa\/informes-de-posicionamiento-terapeutico\/informe-de-posicionamiento-terapeutico-de-dabrafenib-y-trametinib-tafinlar-y-mekinist-en-adyuvancia-de-melanoma\/"},{"issue":"19","key":"4164_CR30","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, Atkinson V, Mandal\u00e0 M, Chiarion-Sileni V, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017;377(19):1813\u201323.","journal-title":"N Engl J Med"},{"issue":"19","key":"4164_CR31","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017;377(19):1824\u201335.","journal-title":"N Engl J Med"},{"issue":"19","key":"4164_CR32","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789\u2013801.","journal-title":"N Engl J Med"},{"key":"4164_CR33","doi-asserted-by":"crossref","unstructured":"- Mu\u00f1oz Couselo E, Berciano-Guerrero M-\u00c1, Manzano JL, et al: 1174P Sex differences in advanced melanoma in spain: result from the prospective real-world study GEM 1801. Ann Oncol. 34(1): 697-698","DOI":"10.1016\/j.annonc.2023.09.2990"},{"issue":"1\u20132","key":"4164_CR34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1053\/j.seminoncol.2023.03.003","volume":"50","author":"L Pala","year":"2023","unstructured":"Pala L, De Pas T, Pagan E, Minucci S, Catania C, Digiacomo N, et al. Improved outcomes in women with BRAF-mutant melanoma treated with BRAF\/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis. Semin Oncol. 2023;50(1\u20132):34\u20139.","journal-title":"Semin Oncol"},{"issue":"1","key":"4164_CR35","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/jamadermatol.2017.4584","volume":"154","author":"M Perier-Muzet","year":"2018","unstructured":"Perier-Muzet M, Gatt E, P\u00e9ron J, Falandry C, Amini-Adl\u00e9 M, Thomas L, et al. Association of immunotherapy with overall survival in elderly patients with melanoma. JAMA Dermatol. 2018;154(1):82\u20137.","journal-title":"JAMA Dermatol"},{"key":"4164_CR36","unstructured":"Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, et al. Androgen receptor blockade promotes response to BRAF\/MEK-targeted therapy. Nature. 2022 Jun;606(7915):797\u2013803. 10.1038\/s41586-022-04833-8. Epub 2022 Jun 15. Erratum in: Nature. 2023 Jan;613(7945):E3. 10.1038\/s41586-022-05632-x. PMID: 35705814; PMCID: PMC10071594"},{"issue":"9","key":"4164_CR37","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.3390\/life12091302.PMID:36143339;PMCID:PMC9505710","volume":"12","author":"MA Berciano-Guerrero","year":"2022","unstructured":"Berciano-Guerrero MA, Guardamagna M, Perez-Ruiz E, Jurado JM, Barrag\u00e1n I, Rueda-Dominguez A. Treatment of metastatic melanoma at first diagnosis: review of the literature. Life (Basel). 2022;12(9):1302. https:\/\/doi.org\/10.3390\/life12091302.PMID:36143339;PMCID:PMC9505710.","journal-title":"Life (Basel)"},{"issue":"9","key":"4164_CR38","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/CJI.0000000000000537","volume":"47","author":"OD Persa","year":"2024","unstructured":"Persa OD, Hassel JC, Steeb T, Erdmann M, Karimi B, Stege H, et al. Brief communication: treatment outcomes for advanced melanoma of unknown primary compared with melanoma with known primary. J Immunother. 2024;47(9):384\u20137. https:\/\/doi.org\/10.1097\/CJI.0000000000000537.","journal-title":"J Immunother"},{"issue":"6","key":"4164_CR39","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1684\/ejd.2020.3929","volume":"30","author":"SV Ludwig","year":"2020","unstructured":"Ludwig SV, Cheng F, P, Mangana J, Braun R, Dummer R, Koelblinger P. Survival and therapeutic response in patients with melanoma of unknown and known primary: a single-centre retrospective analysis. Eur J Dermatol EJD. 2020;30(6):699\u2013709.","journal-title":"Eur J Dermatol EJD."}],"updated-by":[{"DOI":"10.1007\/s12094-026-04430-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000}}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04164-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04164-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04164-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:52:46Z","timestamp":1784181166000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04164-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["4164"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04164-w","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,20]]},"assertion":[{"value":"6 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: to correct the article title.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12094-026-04430-5","URL":"https:\/\/doi.org\/10.1007\/s12094-026-04430-5","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PC-F declares: consulting fees BMS, MSD, Novartis, Pierre Fabre.\n                      IMR\n                      declares Advisory role: Amgen, Astra Zeneca, BiolineRx, BMS, Celegene, GSK, Highlight Therapeutics, Immunocore, Merck Serono, MSD, Novartis, Pierre Fabre, Regeneron, Roche, Sanofi, Sun Pharma \u200b\u200b\u200band \u200bTravel accommodation and congress: Amgen, BMS, GSK, Highlight Therapeutics, MSD, Novartis, Pierre Fabre, Roche, Sun Pharma\u200b\u200b\u200b. EMC declares\n                      Consultant or Advisory Role:\n                      Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi, Regeneron;\n                      Research Funding.\n                      MSD, Sanofi, BMS;\n                      Speaking:\n                      Amgen, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre, Regeneron;\n                      Clinical trial participation (principal investigator):\n                      Amgen, Bristol Myers Squibb, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi, Replimune, Iovance, Bioinvent.\n                      BCB\n                      declares Advisory role: Astra Zeneca, Roche, BeiGene; Speaking: Astra Zeneca, Roche, MSD, Rovi, Sun Pharma, Novartis, Pierre Fabre, BMS, Inmunocore; \u200b\u200b\u200band \u200bTravel accommodation and congress: BMS, Pierre Fabre, Roche, Astra Zeneca, Rovi.\u200b\u200b\u200b LBH declares speaker fees from Astra Zeneca, Amgen, Pierre Fabre, Janssen; and support for attending meetings from MSD, Novartis, Sanofi, Astra Zeneca, Roche, Pierre Fabre, Pfeizer.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patient data will be provided upon reasonable request. Any request should be sent to the corresponding author with a detailed description of the research protocol. The Sponsor reserves the right to decide whether to share the data or not. Access will be provided to the data after the proposal has been approved by an independent review committee established for this purpose.","order":2,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}